Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Reeder

Showing results (431-440 of 465) with videos related to

Pageof 47
Sort By:
Blood Cancer Journal|August 15, 2015
Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomibS K Kumar, B LaPlant, V Roy, et al.
European Radiology|April 26, 2021
Magnetic resonance elastography biomarkers for detection of histologic alterations in nonalcoholic fatty liver disease in the absence of fibrosisYali Qu, Michael S Middleton, Rohit Loomba, et al.
Blood|April 17, 2012
Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trialShaji K Kumar, Suzanne R Hayman, Francis K Buadi, et al.
Blood|July 5, 2024
Multiomics analysis of IgM monoclonal gammopathies reveals epigenetic influence on oncogenesis via DNA methylationKaran Chohan, Jonas Paludo, Surendra Dasari, et al.
American Journal of Hematology|June 2, 2011
Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trialShaji K Kumar, Martha Q Lacy, Suzanne R Hayman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 19, 2022
Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal GammopathiesPatrizia Mondello, Jonas Paludo, Joseph P Novak, et al.
Blood|March 28, 2009
Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasonePrashant Kapoor, Shaji Kumar, Rafael Fonseca, et al.
Hepatology (Baltimore, Md.)|March 25, 2025
Proton density fat fraction for diagnosis of metabolic dysfunction-associated steatotic liver diseaseNikolaos Panagiotopoulos, Tanya Wolfson, David T Harris, et al.
Blood|December 17, 2009
Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patientsFrancesca Gay, Suzanne R Hayman, Martha Q Lacy, et al.
Blood Cancer Journal|November 10, 2018
Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trialsA Castellino, A Chiappella, B R LaPlant, et al.
Pageof 47

Showing results (431-440 of 465) with videos related to

Sort By:
Pageof 47
Blood Cancer Journal|August 15, 2015
Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomibS K Kumar, B LaPlant, V Roy, et al.
European Radiology|April 26, 2021
Magnetic resonance elastography biomarkers for detection of histologic alterations in nonalcoholic fatty liver disease in the absence of fibrosisYali Qu, Michael S Middleton, Rohit Loomba, et al.
Blood|April 17, 2012
Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trialShaji K Kumar, Suzanne R Hayman, Francis K Buadi, et al.
Blood|July 5, 2024
Multiomics analysis of IgM monoclonal gammopathies reveals epigenetic influence on oncogenesis via DNA methylationKaran Chohan, Jonas Paludo, Surendra Dasari, et al.
American Journal of Hematology|June 2, 2011
Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trialShaji K Kumar, Martha Q Lacy, Suzanne R Hayman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 19, 2022
Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal GammopathiesPatrizia Mondello, Jonas Paludo, Joseph P Novak, et al.
Blood|March 28, 2009
Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasonePrashant Kapoor, Shaji Kumar, Rafael Fonseca, et al.
Hepatology (Baltimore, Md.)|March 25, 2025
Proton density fat fraction for diagnosis of metabolic dysfunction-associated steatotic liver diseaseNikolaos Panagiotopoulos, Tanya Wolfson, David T Harris, et al.
Blood|December 17, 2009
Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patientsFrancesca Gay, Suzanne R Hayman, Martha Q Lacy, et al.
Blood Cancer Journal|November 10, 2018
Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trialsA Castellino, A Chiappella, B R LaPlant, et al.
Pageof 47